Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2024 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents...
November 04, 2024 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...
October 24, 2024 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs to Present at Jefferies London Healthcare Conference

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases...
October 01, 2024 16:30 ET | Source: BioAge Labs, Inc.

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...
September 25, 2024 20:00 ET | Source: BioAge Labs, Inc.

BioAge Labs Announces Pricing of Upsized Initial Public Offering

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...
December 03, 2020 08:00 ET | Source: BioAge Labs, Inc.

BioAge Raises $90M to Treat Aging and Age-related Diseases

Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging Company announces Chief Medical Officer as it...
August 25, 2020 08:00 ET | Source: BioAge Labs, Inc.

BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging, a Root Cause of COVID-19 Morbidity and Mortality in Older Patients

BioAge Plans Phase 2 Clinical trial in Hospitalized COVID-19 Patients Clinical development plan supported by potent inhibition of PGD2 DP1 Receptor by BGE-175, activating immune-modulating...
April 29, 2020 22:00 ET | Source: BioAge Labs, Inc.

BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho’s Phase 1 HIF-PH Inhibitor to Treat Aging

RICHMOND, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and age-related diseases, today announced that it has entered into...